Swedish biotech company Ascelia Pharma AB (STO:ACE) said on Wednesday that it has submitted a New Drug Application (NDA) to the US Food and Drug Administration (FDA) for Orviglance.
The company is seeking approval for use of the drug as a liver MRI contrast agent in patients with severe kidney impairment.
The submission is supported by nine clinical studies that demonstrated consistent efficacy and safety results.
Orviglance has already received Orphan Drug Designation from the FDA. The therapy is intended to address the unmet need of patients at high risk of developing nephrogenic systemic fibrosis after exposure to gadolinium-based contrast agents. The global market opportunity for this patient group is estimated at USD800m annually.
The FDA's standard review timeline for the application is 10 months.
DATROWAY receives US priority review for first-line metastatic triple negative breast cancer
Lupin launches Dasatinib tablets in US market
Natera submits Signatera CDx PMA to FDA for bladder cancer use
Pharming receives FDA complete response letter for paediatric Joenja application
Trace Biosciences' IND application for nerve-specific imaging agent approved by FDA
Frontage expands early phase clinical research capabilities across US and China
MicuRx Pharmaceuticals' IND application for MRX-5 cleared by FDA
FDA approves Tenpoint Therapeutics' YUVEZZI as first dual-agent eye drop for presbyopia
Summit Therapeutics' BLA for ivonescimab in EGFR-mutated NSCLC accepted by FDA
WuXi Biologics collaborates with Sinorda Biomedicine for antibody development
Biogen's litifilimab receives FDA Breakthrough Therapy Designation for CLE
Glaukos receives FDA approval for repeat administration of iDose TR
Guerbet's contrast agent Elucirem approved by European Commission in children from birth
Spine Innovation's LOGIC Titanium Implant System receives US FDA 510(k) market approval